An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization
Nicholas Wohlgemuth, Kendall Whitt, Sean Cherry, Ericka Kirkpatrick Roubidoux, Chun-Yang Lin, Kim Allison, Ashleigh Gowen, Pamela Freiden, E. Kaitlynn Allen, St. Jude Investigative Team,, Aditya H. Gaur, Jeremie H. Estepp, Li Tang, Tomi Mori, Diego R. Hijano, Hana Hakim, Maureen A. McGargill, Florian Krammer, Michael A. Whitt, Joshua Wolf, Paul G. Thomas, Stacey Schultz‐Cherry
Abstract
The ongoing COVID-19 pandemic is caused by infection with severe acute respiratory syndrome virus 2 (SARS-CoV-2). Prior infection or vaccination can be detected by the presence of antibodies in the blood. Antibodies in the blood are also considered to be protective against future infections from the same virus. The "gold standard" assay for detecting protective antibodies against SARS-CoV-2 is neutralization of authentic SARS-CoV-2 virus. However, this assay can only be performed under highly restrictive biocontainment conditions. We therefore characterized six antibody-detecting assays for their correlation with authentic virus neutralization. The significance of our research is in outlining the advantages and disadvantages of the different assays and identifying the optimal surrogate assay for authentic virus neutralization. This will allow for more accurate assessments of protective immunity against SARS-CoV-2 following infection and vaccination.